Respiratory Syncytial Virus (RSV) can be a serious threat to the health of premature infants. To protect these vulnerable babies, doctors use monoclonal antibodies, which are lab-made proteins designed to fight specific infections. A review of data from over 11,000 infants looked at three specific options: nirsevimab, motavizumab, and palivizumab.
The findings show that all three treatments successfully reduced the rates of RSV-related hospitalizations and ICU admissions compared to a placebo. While all three were effective, nirsevimab showed the highest ranking for overall therapeutic effects in this analysis.
Safety data indicated no significant differences in drug-related side effects among the three options. However, researchers noted that while these treatments helped prevent serious illness, there was no significant difference found in rates of mechanical ventilation or deaths from RSV. Because these results come from a network meta-analysis, more studies are still needed to confirm these findings fully.
